Mast Therapeutics, Inc. (MSTX) - Financial and Strategic SWOT Analysis Review

Mast Therapeutics, Inc. (MSTX) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Mast Therapeutics, Inc. (Mast Therapeutics) is a biopharmaceutical company, which develops clinical-stage therapies for serious or life-threatening diseases. The company develops therapies for sickle cell disease, a chronic, genetic disorder for rare or orphan disease. The company’s lead product MST-188 (also known as vepoloxamer) is being developed for the treatment of of vaso-occlusive crisis in patients with sickle cell disease. Its pipeline includes development programs in the areas of adjunctive thrombolytic therapy, heart failure, resuscitation and major trauma. The company develops MST-188 utilizing its proprietary technology molecular adhesion and sealant technology (MAST). The company is headquartered in San Diego, California, the US.

Mast Therapeutics, Inc. Key Recent Developments

May 06, 2016: Mast Therapeutics Reports First Quarter 2016 Financial Results And Recent Highlights
Mar 14, 2016: Mast Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results
Jan 07, 2016: Mast Therapeutics Provides Business Update
Nov 12, 2015: Mast Therapeutics Reports Third Quarter 2015 Financial Results
Nov 09, 2015: Mast Therapeutics Announces Appointment Of Peter Greenleaf To Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Mast Therapeutics, Inc. - Key Facts
Mast Therapeutics, Inc. - Key Employees
Mast Therapeutics, Inc. - Key Employee Biographies
Mast Therapeutics, Inc. - Major Products and Services
Mast Therapeutics, Inc. - Pharmaceutical Pipeline Products Data
Mast Therapeutics, Inc., Pipeline Products by Therapy Area
Mast Therapeutics, Inc., Pipeline Products by Development Phase
Mast Therapeutics, Inc. - History
Mast Therapeutics, Inc. - Company Statement
Mast Therapeutics, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Mast Therapeutics, Inc. - Business Description
Mast Therapeutics, Inc. - Corporate Strategy
Mast Therapeutics, Inc. - SWOT Analysis
SWOT Analysis - Overview
Mast Therapeutics, Inc. - Strengths
Strength - Sturdy R&D Activities
Strength - Proprietary Technology: Molecular Adhesion and Sealant Technology (MAST)
Mast Therapeutics, Inc. - Weaknesses
Weakness - Lack of Marketed Products
Weakness - Higher Cost Structure
Mast Therapeutics, Inc. - Opportunities
Opportunity - Rising Healthcare Expenditure in the US
Opportunity - Positive Outlook: Sickle cell disease, Arterial Disease and Heart Failure
Opportunity - Orphan Drug Designation: MS-188
Mast Therapeutics, Inc. - Threats
Threat - Competitive Pressures
Threat - Stringent Government Regulations
Threat - Uncertain R&D Outcomes
Threat - Reliance on Third Party Manufacturers
Mast Therapeutics, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Mast Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Mast Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Mast Therapeutics, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
May 06, 2016: Mast Therapeutics Reports First Quarter 2016 Financial Results And Recent Highlights
Mar 14, 2016: Mast Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results
Jan 07, 2016: Mast Therapeutics Provides Business Update
Nov 12, 2015: Mast Therapeutics Reports Third Quarter 2015 Financial Results
Nov 09, 2015: Mast Therapeutics Announces Appointment Of Peter Greenleaf To Board of Directors
Nov 02, 2015: Mast Therapeutics Announces Appointment Of Matthew Pauls To Board Of Directors
Oct 13, 2015: BASF to Develop a High Purity Poloxamer for Mast Therapeutics
Aug 12, 2015: Mast Therapeutics Reports Second Quarter 2015 Financial Results
May 28, 2015: Mast Therapeutics Announces Change In Board Of Directors
May 11, 2015: Mast Therapeutics Reports First Quarter 2015 Financial Results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Mast Therapeutics, Inc., Key Facts
Mast Therapeutics, Inc., Key Employees
Mast Therapeutics, Inc., Key Employee Biographies
Mast Therapeutics, Inc., Major Products and Services
Mast Therapeutics, Inc., Number of Pipeline Products by Therapy Area
Mast Therapeutics, Inc., Number of Pipeline Products by Development Stage
Mast Therapeutics, Inc., Pipeline Products By Therapy Area and Development Phase
Mast Therapeutics, Inc., History
Mast Therapeutics, Inc., Subsidiaries
Mast Therapeutics, Inc., Key Competitors
Mast Therapeutics, Inc., Ratios based on current share price
Mast Therapeutics, Inc., Annual Ratios
Mast Therapeutics, Inc., Interim Ratios
Mast Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Mast Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Mast Therapeutics, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Mast Therapeutics, Inc., Pipeline Products by Therapy Area
Mast Therapeutics, Inc., Pipeline Products by Development Phase
Mast Therapeutics, Inc., Performance Chart (2011 - 2015)
Mast Therapeutics, Inc., Ratio Charts
Mast Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Mast Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook